nicardipine has been researched along with Brain Neoplasms in 13 studies
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-two subjects were prospectively randomized to receive either nicardipine or esmolol as the sole drug for treatment of emergence hypertension at the conclusion of brain tumor resection (40 subjects finally analyzed)." | 9.20 | Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study. ( Badri, AM; Bebawy, JF; Carabini, LM; Gupta, DK; Hemmer, LB; Houston, CC; Koht, A; Kosky, JL; Moreland, NC, 2015) |
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 9.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| " However, whether glioma stem cells (GSCs) can be sensitized to chemotherapy via combined treatment with temozolomide (TMZ) and nicardipine is unclear." | 8.02 | Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells. ( Dong, J; Dong, X; Jiang, Q; Li, H; Liu, L; Shi, J; Wang, H; Wang, L, 2021) |
| "Using the monolay tumor cell culture system and the method or MTT colorimetric analysis, the cytotoxicity of the anticancer drug VM-26 and Nicardipine(NCDP) in human malignant glioma cell line U251 was studied." | 7.70 | [Enhanced cytotoxicity of VM-26 in human malignant glioma cells by calcium channel blocker nicardipine in vitro]. ( Chen, B; Hu, S; Huang, C, 1999) |
| "Fifty-two subjects were prospectively randomized to receive either nicardipine or esmolol as the sole drug for treatment of emergence hypertension at the conclusion of brain tumor resection (40 subjects finally analyzed)." | 5.20 | Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study. ( Badri, AM; Bebawy, JF; Carabini, LM; Gupta, DK; Hemmer, LB; Houston, CC; Koht, A; Kosky, JL; Moreland, NC, 2015) |
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 5.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| " However, whether glioma stem cells (GSCs) can be sensitized to chemotherapy via combined treatment with temozolomide (TMZ) and nicardipine is unclear." | 4.02 | Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells. ( Dong, J; Dong, X; Jiang, Q; Li, H; Liu, L; Shi, J; Wang, H; Wang, L, 2021) |
| "Using the monolay tumor cell culture system and the method or MTT colorimetric analysis, the cytotoxicity of the anticancer drug VM-26 and Nicardipine(NCDP) in human malignant glioma cell line U251 was studied." | 3.70 | [Enhanced cytotoxicity of VM-26 in human malignant glioma cells by calcium channel blocker nicardipine in vitro]. ( Chen, B; Hu, S; Huang, C, 1999) |
| "Membrane-modifying agents such as reserpine, calcium antagonists (nicardipine, verapamil) and calmodulin inhibitor (trifluoperazine) were found to enhance the cytotoxicity of ACNU in vitro and in vivo in ACNU-resistant C 6 (C 6/ACNU) glioma." | 3.67 | [Possibility of overcoming of ACNU resistance in an ACNU-resistant subline of C6 rat glioma]. ( Mogami, H; Sakamoto, Y; Shimizu, K; Ushio, Y; Yoshida, T, 1986) |
| "2 Gy) combined with radiosensitizing agents." | 2.67 | Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults. ( Asai, A; Fujimaki, T; Matsutani, M; Nagashima, T; Nakamura, M; Nakamura, O; Tanaka, H; Tanaka, Y; Ueki, K, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, J | 1 |
| Dong, X | 1 |
| Li, H | 1 |
| Wang, H | 1 |
| Jiang, Q | 1 |
| Liu, L | 1 |
| Wang, L | 1 |
| Dong, J | 1 |
| Bebawy, JF | 1 |
| Houston, CC | 1 |
| Kosky, JL | 1 |
| Badri, AM | 1 |
| Hemmer, LB | 1 |
| Moreland, NC | 1 |
| Carabini, LM | 1 |
| Koht, A | 1 |
| Gupta, DK | 1 |
| Jin, Y | 1 |
| Bin, ZQ | 1 |
| Qiang, H | 1 |
| Liang, C | 1 |
| Hua, C | 1 |
| Jun, D | 1 |
| Dong, WA | 1 |
| Qing, L | 1 |
| Hanak, BW | 1 |
| Walcott, BP | 1 |
| Nahed, BV | 1 |
| Muzikansky, A | 1 |
| Mian, MK | 1 |
| Kimberly, WT | 1 |
| Curry, WT | 1 |
| Huang, CX | 1 |
| Chen, B | 2 |
| Zhang, YF | 1 |
| Nomura, K | 1 |
| Watanabe, T | 1 |
| Nakamura, O | 2 |
| Shibui, S | 1 |
| Matsutani, M | 1 |
| Nakamura, M | 1 |
| Nagashima, T | 1 |
| Asai, A | 1 |
| Fujimaki, T | 1 |
| Tanaka, H | 1 |
| Ueki, K | 1 |
| Tanaka, Y | 1 |
| Saqr, HE | 1 |
| Guan, Z | 1 |
| Yates, AJ | 1 |
| Stokes, BT | 1 |
| Kross, RA | 1 |
| Ferri, E | 1 |
| Leung, D | 1 |
| Pratila, M | 1 |
| Broad, C | 1 |
| Veronesi, M | 1 |
| Melendez, JA | 1 |
| Hu, S | 1 |
| Huang, C | 1 |
| Yoshida, T | 2 |
| Shimizu, K | 2 |
| Ushio, Y | 2 |
| Hayakawa, T | 1 |
| Kato, A | 1 |
| Mogami, H | 2 |
| Sakamoto, Y | 2 |
| Kaba, K | 1 |
| Tani, E | 1 |
| Morimura, T | 1 |
| Matsumoto, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficiency of Intravenous Lidocaine to Reduce Coughing and the Hemodynamic Changes Associated to Tracheal Extubation[NCT03731429] | Phase 4 | 144 participants (Anticipated) | Interventional | 2019-04-05 | Recruiting | ||
| Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy[NCT01951950] | Phase 1 | 40 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01951950)
Timeframe: 1 hour postoperatively
| Intervention | participants (Number) |
|---|---|
| Nicardipine | 1 |
| Esmolol | 11 |
3 trials available for nicardipine and Brain Neoplasms
| Article | Year |
|---|---|
Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study.
Topics: Aged; Anesthesia Recovery Period; Antihypertensive Agents; Brain Neoplasms; Craniotomy; Female; Huma | 2015 |
Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 1994 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
10 other studies available for nicardipine and Brain Neoplasms
| Article | Year |
|---|---|
Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Calcium Channel Blockers; | 2021 |
ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
Postoperative intensive care unit requirements after elective craniotomy.
Topics: Adult; Aged; Brain Neoplasms; Calcium Channel Blockers; Craniotomy; Critical Care; Elective Surgical | 2014 |
[Growth inhibition of epidermal growth factor-stimulated human glioblastoma cells by nicardipine in vito].
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Division; Culture Media, Serum-Free; Epidermal Growth F | 2001 |
[Flow cytometric study of enhanced effect of anti-cancer drugs induced by nicardipine hydrochloride].
Topics: Animals; Brain Neoplasms; Cell Division; Cells, Cultured; DNA, Neoplasm; Doxorubicin; Flow Cytometry | 1984 |
Mechanisms through which PDGF alters intracellular calcium levels in U-1242 MG human glioma cells.
Topics: Becaplermin; Brain Neoplasms; Caffeine; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium | 1999 |
[Enhanced cytotoxicity of VM-26 in human malignant glioma cells by calcium channel blocker nicardipine in vitro].
Topics: Antineoplastic Agents; Brain Neoplasms; Calcium Channel Blockers; Drug Synergism; Glioma; Humans; Ni | 1999 |
[Mechanism and overcoming of resistance in ACNU-resistant sublines of rat brain tumors].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Membrane Permeability; Drug Resistance; Glioma | 1986 |
[Possibility of overcoming of ACNU resistance in an ACNU-resistant subline of C6 rat glioma].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Cells, Cultured; Drug Resistance; Drug T | 1986 |
Potentiation of vincristine effect in human and murine gliomas by calcium channel blockers or calmodulin inhibitors.
Topics: Animals; Brain Neoplasms; Calcium Channel Blockers; Calmodulin; Drug Synergism; Glioma; Humans; In V | 1985 |